In the past 15 years, HIV infection in the U.S. has gone from a potential epidemic to a manageable disease providing steady revenue for drugmakers. As always, companies including Gilead Sciences (GILD) and OraSure Technologies (OSUR) are developing new products both to improve care and bolster their own finances. The current batch working their way through the regulatory pipeline could do both, but a lot depends on patients' responsibility and, in